What is Medlab?
Medlab, Inc. operates as a sophisticated clinical laboratory entity, delivering high-precision services across toxicology, molecular diagnostics, and pain management testing. By integrating advanced PCR testing capabilities for respiratory pathogens such as COVID-19, Flu, and RSV, the company serves a critical role in the healthcare ecosystem. Its service model is specifically engineered to support healthcare providers, judicial systems, and community health organizations, offering rapid turnaround times that are essential for effective clinical decision-making and patient management. The company's commitment to diagnostic accuracy and insurance-backed accessibility positions it as a vital partner for institutions managing complex health issues, including chronic pain and substance abuse.
How much funding has Medlab raised?
Medlab has raised a total of $16.3M across 2 funding rounds:
Series D
$16M
Debt
$250K
Series D (2008): $16M with participation from Primus Capital, Chrysalis Ventures, and Oxford Bioscience Partners
Debt (2025): $250K led by M&T Bank
Key Investors in Medlab
Primus Capital
Primus Capital is a U.S. based growth-oriented private equity firm that invests in healthcare, software, and technology-enabled services companies, providing equity capital for buyouts and expansion financings.
Chrysalis Ventures
Chrysalis Ventures is an investment firm that partners with proven operators in markets underserved by technology, focusing on building enduring value in healthcare and logistics sectors.
Oxford Bioscience Partners
Oxford Bioscience Partners is an international venture capital firm specializing in life science technology-based investments, with a global footprint spanning Boston and Seoul.
What's next for Medlab?
The recent injection of capital is expected to catalyze Medlab's operational expansion and technological integration. By leveraging this major strategic investment, the company is well-positioned to enhance its laboratory throughput and broaden its diagnostic portfolio. Future initiatives will likely focus on optimizing supply chain efficiencies and expanding the reach of its molecular diagnostic services to meet the growing demand for rapid, reliable health data. As the firm navigates this next phase of growth, the focus remains on maintaining high-quality standards while scaling its infrastructure to support a wider network of healthcare professionals and community stakeholders, ultimately reinforcing its market leadership in the diagnostic sector.
See full Medlab company page
